[
  {
    "question": "Young lady with SLE complained of a seizures and confusion this time. SLE nephritis on dialysis What is your diagnosis? Image including multiple lesion not only cortical involvment",
    "option_a": "(Intracerebral hemorrhage) is unlikely because hemorrhage classically produces focal neurological deficits and distinct imaging findings of hyperdensity. Option B (Cerebral venous thrombosis) would typically show venous occlusion and associated hemorrhagic infarcts confined to venous territories. Option C (PRES) correlates best with the clinical scenario and imaging findings. Option D (Lupus cerebritis) is generally a diagnosis of exclusion and does not produce the classic reversible multifocal vasogenic edema seen in PRES.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuroimmunology",
    "explanation": "PRES (Posterior Reversible Encephalopathy Syndrome) is a clinico\u2010radiological syndrome characterized by symptoms such as headache, seizures, confusion, and visual disturbances. It is commonly seen in patients with conditions that predispose to blood pressure fluctuations and endothelial dysfunction (e.g., SLE, renal failure, eclampsia, immunosuppressive therapies). PRES results from a failure of cerebral autoregulation when blood pressure surges lead to hyperperfusion and subsequent endothelial injury. This breakdown of the blood-brain barrier results in vasogenic edema predominantly in the posterior cerebral regions, though the involvement can be more diffuse. In SLE patients with nephritis on dialysis, uremia and marked hypertension further contribute to this process. Patients typically present with acute neurological symptoms including seizures, altered mental status (confusion), and sometimes visual deficits. The imaging pattern on MRI\u2014showing multifocal, often bilateral, vasogenic edema that is not strictly limited to the cortex\u2014strongly supports the diagnosis of PRES in the appropriate clinical context. The diagnosis is made by correlating the clinical presentation with neuroimaging. Differential diagnoses include intracerebral hemorrhage (which often presents with focal deficits and hyperdense hemorrhagic lesions on CT/MRI), cerebral venous thrombosis (with signs of venous sinus occlusion and hemorrhagic infarcts), and lupus cerebritis (which lacks the typical reversible vasogenic edema pattern). MRI with T2/FLAIR sequences is the imaging modality of choice. Management focuses on prompt blood pressure control using agents such as labetalol or nicardipine, seizure management with appropriate antiepileptics, and removal or reduction of precipitating factors. In pregnant patients or those who are lactating, agents like labetalol are preferred due to their safety profile, and magnesium sulfate may be used in cases of eclampsia-related PRES. Option A (Intracerebral hemorrhage) is unlikely because hemorrhage classically produces focal neurological deficits and distinct imaging findings of hyperdensity. Option B (Cerebral venous thrombosis) would typically show venous occlusion and associated hemorrhagic infarcts confined to venous territories. Option C (PRES) correlates best with the clinical scenario and imaging findings. Option D (Lupus cerebritis) is generally a diagnosis of exclusion and does not produce the classic reversible multifocal vasogenic edema seen in PRES. 1. PRES is reversible with early recognition and appropriate management of blood pressure and other triggers. 2. In patients with SLE and renal failure, always consider PRES when neurological symptoms appear, even if imaging shows diffuse rather than strictly posterior involvement. Current research continues to support aggressive management of blood pressure as the cornerstone of PRES treatment. Recent advances in MRI techniques (including diffusion-weighted imaging) have improved the accuracy in differentiating vasogenic from cytotoxic edema, reinforcing the diagnostic approach.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Mechanism of actions ocrilezumab:",
    "option_a": "Shift of lymphocyte from pro inflammatory to anti inflammatory",
    "option_b": "Binds to \u03b14\u03b21-integrin and blocks its interaction with VCAM-1",
    "option_c": "Monoclonal CD 20 antibody",
    "option_d": "Monoclonal CD 25 antibody",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "PRES (Posterior Reversible Encephalopathy Syndrome) is a clinico\u2010radiological syndrome characterized by symptoms such as headache, seizures, confusion, and visual disturbances. It is commonly seen in patients with conditions that predispose to blood pressure fluctuations and endothelial dysfunction (e.g., SLE, renal failure, eclampsia, immunosuppressive therapies). PRES results from a failure of cerebral autoregulation when blood pressure surges lead to hyperperfusion and subsequent endothelial injury. This breakdown of the blood-brain barrier results in vasogenic edema predominantly in the posterior cerebral regions, though the involvement can be more diffuse. In SLE patients with nephritis on dialysis, uremia and marked hypertension further contribute to this process. Patients typically present with acute neurological symptoms including seizures, altered mental status (confusion), and sometimes visual deficits. The imaging pattern on MRI\u2014showing multifocal, often bilateral, vasogenic edema that is not strictly limited to the cortex\u2014strongly supports the diagnosis of PRES in the appropriate clinical context. The diagnosis is made by correlating the clinical presentation with neuroimaging. Differential diagnoses include intracerebral hemorrhage (which often presents with focal deficits and hyperdense hemorrhagic lesions on CT/MRI), cerebral venous thrombosis (with signs of venous sinus occlusion and hemorrhagic infarcts), and lupus cerebritis (which lacks the typical reversible vasogenic edema pattern). MRI with T2/FLAIR sequences is the imaging modality of choice. Management focuses on prompt blood pressure control using agents such as labetalol or nicardipine, seizure management with appropriate antiepileptics, and removal or reduction of precipitating factors. In pregnant patients or those who are lactating, agents like labetalol are preferred due to their safety profile, and magnesium sulfate may be used in cases of eclampsia-related PRES. Option A (Intracerebral hemorrhage) is unlikely because hemorrhage classically produces focal neurological deficits and distinct imaging findings of hyperdensity. Option B (Cerebral venous thrombosis) would typically show venous occlusion and associated hemorrhagic infarcts confined to venous territories. Option C (PRES) correlates best with the clinical scenario and imaging findings. Option D (Lupus cerebritis) is generally a diagnosis of exclusion and does not produce the classic reversible multifocal vasogenic edema seen in PRES. 1. PRES is reversible with early recognition and appropriate management of blood pressure and other triggers. 2. In patients with SLE and renal failure, always consider PRES when neurological symptoms appear, even if imaging shows diffuse rather than strictly posterior involvement. Current research continues to support aggressive management of blood pressure as the cornerstone of PRES treatment. Recent advances in MRI techniques (including diffusion-weighted imaging) have improved the accuracy in differentiating vasogenic from cytotoxic edema, reinforcing the diagnostic approach.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "28 yo female k/c of MS on natalizumab, presented with left side weakness / visual disturbance, received 5 days of MTX with no respond. Found to have positive neutralizing antibody natalizumab. MRI showed evidence of new lesion. What to do next:",
    "option_a": "IVIG",
    "option_b": "PLEX 5 session",
    "option_c": "Give more MTX for 3 days",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "PRES (Posterior Reversible Encephalopathy Syndrome) is a clinico\u2010radiological syndrome characterized by symptoms such as headache, seizures, confusion, and visual disturbances. It is commonly seen in patients with conditions that predispose to blood pressure fluctuations and endothelial dysfunction (e.g., SLE, renal failure, eclampsia, immunosuppressive therapies). PRES results from a failure of cerebral autoregulation when blood pressure surges lead to hyperperfusion and subsequent endothelial injury. This breakdown of the blood-brain barrier results in vasogenic edema predominantly in the posterior cerebral regions, though the involvement can be more diffuse. In SLE patients with nephritis on dialysis, uremia and marked hypertension further contribute to this process. Patients typically present with acute neurological symptoms including seizures, altered mental status (confusion), and sometimes visual deficits. The imaging pattern on MRI\u2014showing multifocal, often bilateral, vasogenic edema that is not strictly limited to the cortex\u2014strongly supports the diagnosis of PRES in the appropriate clinical context. The diagnosis is made by correlating the clinical presentation with neuroimaging. Differential diagnoses include intracerebral hemorrhage (which often presents with focal deficits and hyperdense hemorrhagic lesions on CT/MRI), cerebral venous thrombosis (with signs of venous sinus occlusion and hemorrhagic infarcts), and lupus cerebritis (which lacks the typical reversible vasogenic edema pattern). MRI with T2/FLAIR sequences is the imaging modality of choice. Management focuses on prompt blood pressure control using agents such as labetalol or nicardipine, seizure management with appropriate antiepileptics, and removal or reduction of precipitating factors. In pregnant patients or those who are lactating, agents like labetalol are preferred due to their safety profile, and magnesium sulfate may be used in cases of eclampsia-related PRES. Option A (Intracerebral hemorrhage) is unlikely because hemorrhage classically produces focal neurological deficits and distinct imaging findings of hyperdensity. Option B (Cerebral venous thrombosis) would typically show venous occlusion and associated hemorrhagic infarcts confined to venous territories. Option C (PRES) correlates best with the clinical scenario and imaging findings. Option D (Lupus cerebritis) is generally a diagnosis of exclusion and does not produce the classic reversible multifocal vasogenic edema seen in PRES. 1. PRES is reversible with early recognition and appropriate management of blood pressure and other triggers. 2. In patients with SLE and renal failure, always consider PRES when neurological symptoms appear, even if imaging shows diffuse rather than strictly posterior involvement. Current research continues to support aggressive management of blood pressure as the cornerstone of PRES treatment. Recent advances in MRI techniques (including diffusion-weighted imaging) have improved the accuracy in differentiating vasogenic from cytotoxic edema, reinforcing the diagnostic approach.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "This is 40 yo female African came to work in SA few month ago, presented with history of back pain, gradual bilateral weakness, numbness, sphincter issue. CSF unpaired band of OCB. MRI showed long extensive T2 hyper-intensity from thoracic to cuda-aquaina. What is the DDx:",
    "option_a": "HIV",
    "option_b": "Human T lymphotropic virus type 1",
    "option_c": "CMV",
    "option_d": "progressive MS",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "PRES (Posterior Reversible Encephalopathy Syndrome) is a clinico\u2010radiological syndrome characterized by symptoms such as headache, seizures, confusion, and visual disturbances. It is commonly seen in patients with conditions that predispose to blood pressure fluctuations and endothelial dysfunction (e.g., SLE, renal failure, eclampsia, immunosuppressive therapies). PRES results from a failure of cerebral autoregulation when blood pressure surges lead to hyperperfusion and subsequent endothelial injury. This breakdown of the blood-brain barrier results in vasogenic edema predominantly in the posterior cerebral regions, though the involvement can be more diffuse. In SLE patients with nephritis on dialysis, uremia and marked hypertension further contribute to this process. Patients typically present with acute neurological symptoms including seizures, altered mental status (confusion), and sometimes visual deficits. The imaging pattern on MRI\u2014showing multifocal, often bilateral, vasogenic edema that is not strictly limited to the cortex\u2014strongly supports the diagnosis of PRES in the appropriate clinical context. The diagnosis is made by correlating the clinical presentation with neuroimaging. Differential diagnoses include intracerebral hemorrhage (which often presents with focal deficits and hyperdense hemorrhagic lesions on CT/MRI), cerebral venous thrombosis (with signs of venous sinus occlusion and hemorrhagic infarcts), and lupus cerebritis (which lacks the typical reversible vasogenic edema pattern). MRI with T2/FLAIR sequences is the imaging modality of choice. Management focuses on prompt blood pressure control using agents such as labetalol or nicardipine, seizure management with appropriate antiepileptics, and removal or reduction of precipitating factors. In pregnant patients or those who are lactating, agents like labetalol are preferred due to their safety profile, and magnesium sulfate may be used in cases of eclampsia-related PRES. Option A (Intracerebral hemorrhage) is unlikely because hemorrhage classically produces focal neurological deficits and distinct imaging findings of hyperdensity. Option B (Cerebral venous thrombosis) would typically show venous occlusion and associated hemorrhagic infarcts confined to venous territories. Option C (PRES) correlates best with the clinical scenario and imaging findings. Option D (Lupus cerebritis) is generally a diagnosis of exclusion and does not produce the classic reversible multifocal vasogenic edema seen in PRES. 1. PRES is reversible with early recognition and appropriate management of blood pressure and other triggers. 2. In patients with SLE and renal failure, always consider PRES when neurological symptoms appear, even if imaging shows diffuse rather than strictly posterior involvement. Current research continues to support aggressive management of blood pressure as the cornerstone of PRES treatment. Recent advances in MRI techniques (including diffusion-weighted imaging) have improved the accuracy in differentiating vasogenic from cytotoxic edema, reinforcing the diagnostic approach.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "32 yo female with bilateral blurry vision with decrease in visual acuity. MRI brain normal. Later she had history of paraplesia, numbness, sphincter dysfunction. ANA positive, AQP-4 antibody negative, CSF OCB negative. MRI showed increase signal from T6 - T10. What is the diagnosis:",
    "option_a": "Progressive MS",
    "option_b": "NMOSD",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease distinct from multiple sclerosis (MS). It is characterized by recurrent episodes of optic neuritis and longitudinally extensive transverse myelitis, typically involving three or more vertebral segments. NMOSD is most often mediated by antibodies against aquaporin-4 (AQP4) water channels on astrocytes. This antibody\u2010mediated astrocytopathy triggers complement activation and inflammation. However, up to 30% of patients may be seronegative for AQP4 antibodies. ANA positivity is common in autoimmune disorders and may be incidentally positive or indicate an overlapping autoimmune process. Patients often present with severe optic nerve involvement (which may cause bilateral blurred vision and decreased acuity) and later develop a transverse myelitis picture with paraplegia, sensory deficits, and sphincter dysfunction. The MRI finding of a longitudinally extensive lesion (from T6 to T10 in this case) is highly characteristic of NMOSD as opposed to the typically multifocal, brain\u2010predominant lesions seen in MS. Diagnosis is based on the clinical picture and imaging findings. Key differentiators include: (1) longitudinally extensive spinal cord lesions (\u22653 vertebral segments) seen on MRI, (2) serologic testing for AQP4 antibodies (with the understanding that some patients can be seronegative), and (3) typically negative cerebrospinal fluid oligoclonal bands (OCBs) compared to MS. Differential diagnoses include multiple sclerosis, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease, and other autoimmune myelopathies. Acute attacks are typically managed with high-dose intravenous corticosteroids, with plasmapheresis reserved for refractory cases. Long-term management involves immunosuppressive therapies (e.g., rituximab, mycophenolate mofetil, azathioprine) rather than traditional MS disease-modifying therapies. In pregnancy, high-dose steroids may be used for acute relapses, and immunosuppressives require a careful risk-benefit discussion with multidisciplinary input to minimize fetal risks. Option A (Progressive MS) is inconsistent with the imaging findings and CSF profile (absence of OCB), while Option B (NMOSD) best fits the clinical picture of recurrent optic neuritis and longitudinally extensive transverse myelitis. Options C and D were not provided. 1. Longitudinally extensive spinal cord lesions (\u22653 vertebral segments) strongly favor NMOSD over MS. 2. CSF oligoclonal bands are typically negative in NMOSD. 3. AQP4 seronegativity does not exclude the diagnosis if clinical and radiologic criteria are met. The 2015 International Panel criteria for NMOSD have refined diagnostic approaches, emphasizing core clinical features and MRI findings even in seronegative patients. Emerging treatments targeting complement pathways are under investigation and show promise in reducing relapse rates.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "This is 30 yo female presented with 18 months history of back pain, weakness, numbness, sphincter issues. On exam there was sensory level up to T10, planter up-going, ankle reflexes absent. MRI thoracic spine show high signal T2, with hypo intense center. What is the diagnosis?",
    "option_a": "Dural venous visual",
    "option_b": "Progressive MS",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Spinal dural arteriovenous fistula (SDAVF) is a vascular malformation characterized by an abnormal connection between a dural artery and a radicular vein, leading to venous congestion of the spinal cord. The fistula creates a shunt that results in elevated venous pressure and chronic venous hypertension. This, in turn, leads to cord edema, myelopathy, and eventual ischemic damage. The MRI often shows T2 hyperintensity due to edema with areas of hypointense signal representing flow voids from abnormal vessels. Patients typically present with gradually progressive symptoms over months to years, including back pain, motor weakness, sensory disturbances (with a defined sensory level) and sphincter dysfunction. While SDAVF is more common in older males, it can also be seen in younger females. The combination of UMN signs (positive Babinski) and sometimes reduced deep tendon reflexes due to early cord involvement fits the clinical picture. MRI is the first imaging modality, which typically reveals a T2 hyperintense signal in the cord with central areas of low signal intensity (flow voids). Spinal angiography is the gold standard for confirming the diagnosis. Differential diagnoses include multiple sclerosis (which usually shows multifocal white matter lesions including brain involvement), transverse myelitis of inflammatory etiology, and compressive myelopathies. Treatment centers on occluding the fistula to relieve venous hypertension, typically via endovascular embolization or surgical ligation. Timely intervention is crucial to halt progression and potentially reverse neurological deficits. During pregnancy, the management approach must weigh risks, and careful coordination with neurosurgery and obstetrical teams is required. Endovascular techniques may be modified for safety considerations in pregnant patients, and lactating mothers need counseling regarding radiologic procedures and anesthetic exposures. Option A (labeled as 'Dural venous visual') is intended to represent the diagnosis of a spinal dural arteriovenous fistula, which best fits the MRI findings and clinical presentation. Option B (Progressive MS) is less likely given the focal long-segment spinal cord lesion with central hypointensity, rather than multifocal lesions with typical MS distribution. Options C and D were not provided. 1. A long-segment T2 hyperintensity with central flow voids on spinal MRI is highly suggestive of SDAVF. 2. Early diagnosis and treatment of SDAVF are crucial to prevent irreversible spinal cord damage. 3. Although more common in men of middle age, SDAVF should be considered in any patient with progressive myelopathy. Recent literature emphasizes improved outcomes with early endovascular or surgical treatment of SDAVF. Advances in imaging techniques have led to earlier recognition, and current guidelines advocate for prompt intervention to reduce long\u2010term disability.",
    "exam_year": "2022",
    "exam_type": "Promotion"
  },
  {
    "question": "Case of primary progressive MS with typical MRI features and normal csf. What increases walking speed?",
    "option_a": "4-pyridine thing",
    "option_b": "Ocrelizumab",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "In multiple sclerosis (MS), particularly in cases with walking impairment, symptomatic treatments are used to enhance conduction in demyelinated nerve fibers. Dalfampridine (a sustained-release formulation of 4-aminopyridine) is the only FDA-approved medication for improving walking speed in MS patients. 4-Aminopyridine acts as a potassium channel blocker. In demyelinated axons, potassium channels become exposed and lead to conduction failure. By blocking these channels, dalfampridine improves action potential propagation and neuronal conduction, thereby improving motor function. Patients with primary progressive MS often experience gait difficulties. Even when the disease-modifying treatment might not elicit acute symptomatic improvement, dalfampridine has been shown in clinical trials to increase walking speed and improve ambulation in MS patients. This is a treatment decision rather than a diagnostic dilemma. In patients with confirmed MS (with typical MRI features and normal CSF in this case), detailed assessment of gait impairment (such as the Timed 25-Foot Walk) is used to evaluate baseline function and response to therapy. The first-line symptomatic therapy for gait impairment in MS is dalfampridine (4-aminopyridine), which can improve walking speed. Disease-modifying therapies (such as ocrelizumab) are intended to slow progression but do not directly improve walking speed on an acute basis. In pregnancy, the use of dalfampridine requires caution due to limited safety data; benefits must be balanced against potential risks, and similar considerations apply during lactation. Option A (4-aminopyridine) is the correct symptomatic treatment for improving walking speed. Option B (ocrelizumab), while approved as a disease-modifying therapy for primary progressive MS, is not indicated for the symptomatic improvement of walking speed as its primary benefit is in slowing disability progression. Options C and D were not provided. 1. Dalfampridine is the only agent shown to improve walking speed in MS and works via potassium channel blockade. 2. Its use is strictly symptomatic and does not modify the underlying disease progression. 3. Always assess gait function objectively before and after therapy using standardized tests like the Timed 25-Foot Walk. Recent studies and guideline updates support the use of dalfampridine in MS patients with significant gait impairment. Although newer disease-modifying treatments such as ocrelizumab are available for primary progressive MS, their impact on symptomatic walking speed is indirect.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Female known case of MS for long time on fingolimod came with spasticity and gait issues her MRI no active disease what to do next for the gait",
    "option_a": "(natalizumab) is designed to reduce relapse rates in active MS and is not indicated here since the MRI shows no active disease. Option B (glatiramer acetate) is a first",
    "option_b": "",
    "option_c": "(steroids) is reserved for acute inflammatory relapses, which is not the case here. Option D (aminopyridine) is the approved symptomatic agent for improving walking speed in MS, making it the correct answer.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "In long-standing multiple sclerosis (MS) with stable inflammatory activity on MRI, residual symptoms like spasticity and gait disturbances are addressed with symptomatic therapies rather than altering disease-modifying treatment. Chronic demyelination in MS results in impaired conduction along axons. Aminopyridines (such as dalfampridine) improve conduction by blocking potassium channels on demyelinated nerve fibers, thereby enhancing action potential transmission and improving motor function. Patients on established disease-modifying therapies (like fingolimod) who develop gait disturbances but have no active disease on MRI are often suffering from chronic deficits. In this setting, switching to another immunomodulator is not helpful. Instead, symptomatic treatment to enhance conduction can lead to improvement in gait and spasticity. Since the MRI shows no active lesions (indicative of stable disease), workup focuses on managing chronic symptoms. Differential considerations such as an undetected relapse or medication side effects should be ruled out, but here the clinical picture clearly favors symptomatic management. For chronic gait impairment in stable MS, first-line symptomatic treatment is with aminopyridines (e.g., dalfampridine). Alternative strategies such as physiotherapy, rehabilitative exercises, and occasionally antispasmodics may be considered. Escalation of immunomodulatory treatment (like natalizumab or glatiramer acetate) or use of steroids is not indicated in the absence of active inflammation. In pregnancy, the use of symptomatic medications requires a careful risk-benefit assessment due to limited safety data; non-pharmacologic interventions and physiotherapy are often preferred, while lactating mothers also require counseling regarding medication exposure. Option A (natalizumab) is designed to reduce relapse rates in active MS and is not indicated here since the MRI shows no active disease. Option B (glatiramer acetate) is a first-line DMT for relapsing forms of MS and does not address established symptoms like spasticity or gait issues. Option C (steroids) is reserved for acute inflammatory relapses, which is not the case here. Option D (aminopyridine) is the approved symptomatic agent for improving walking speed in MS, making it the correct answer. 1. In stable MS patients with chronic symptoms, symptomatic treatment (such as with aminopyridines) is preferable over unnecessary changes in disease-modifying therapy. 2. Aminopyridine improves conduction in demyelinated axons and can enhance gait function. 3. Always verify disease activity with imaging before changing immunomodulatory therapy. Recent guidelines and controlled trials have reinforced the benefit of dalfampridine (4-aminopyridine) in improving walking speed in MS patients with gait disturbances. Its use is reserved strictly for symptomatic improvement, with current research focusing on optimizing dosing and minimizing side effects such as seizures.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Same q they added upon workup you find ovarian teratoma what is best",
    "option_a": "is correct because it targets both the source of the antigen (the teratoma) and the autoimmune process, which has been shown to improve outcomes. Option B (immunotherapy without tumor removal) may leave the antigenic source intact, Option C (symptomatic treatment only) fails to address the underlying mechanism, Option D (observation) risks irreversible damage, and Option E (chemotherapy) is inappropriate given the benign nature of most teratomas.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question pertains to anti\u2010NMDAR encephalitis, a paraneoplastic autoimmune disorder that is closely associated with ovarian teratomas. The immune system attacks NMDA receptors in the brain, and the presence of a teratoma provides a source of neural antigens. Ovarian teratomas may harbor neural tissue expressing NMDA receptors. In susceptible individuals, this triggers an antibody\u2010mediated autoimmune response that targets brain tissue, leading to neuropsychiatric symptoms. Removal of the teratoma eliminates the antigenic stimulus, while immunotherapy dampens the autoimmune response. Patients often present with psychiatric changes, memory disturbances, seizures, and movement disorders. The identification of an ovarian teratoma in a patient with suspected anti\u2010NMDAR encephalitis is a critical clue, as it directly influences the management strategy. The diagnosis is supported by cerebrospinal fluid (CSF) analysis showing anti-NMDAR antibodies, neuroimaging such as brain MRI, and pelvic imaging (ultrasound, CT, or MRI) for detecting an ovarian teratoma. Differential diagnoses include infectious encephalitis and other forms of autoimmune encephalitis. First-line management involves the surgical resection of the ovarian teratoma combined with immunotherapy (e.g., high-dose corticosteroids, IVIG, or plasmapheresis). In pregnant or lactating patients, a multidisciplinary team is essential: surgical resection is optimally performed in the second trimester when possible, while immunotherapies such as steroids and IVIG have a favorable safety profile if used judiciously. Option A is correct because it targets both the source of the antigen (the teratoma) and the autoimmune process, which has been shown to improve outcomes. Option B (immunotherapy without tumor removal) may leave the antigenic source intact, Option C (symptomatic treatment only) fails to address the underlying mechanism, Option D (observation) risks irreversible damage, and Option E (chemotherapy) is inappropriate given the benign nature of most teratomas. 1. Anti-NMDAR encephalitis is strongly linked to ovarian teratomas and often affects young women. 2. Early tumor resection combined with immunotherapy is key to a favorable outcome. 3. Delay in treatment can increase the risk of relapse and long-term neurological deficits. Recent studies emphasize that early surgical removal of the teratoma, combined with immunotherapy, is associated with rapid clinical improvement and lower relapse rates. Updated guidelines continue to support this dual approach to address both the autoimmune and neoplastic components.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Female case of MS on fingolimod for long time, pw decrease vision and has decrease acuity in one eye no eye pain what is next in management",
    "option_a": "(stopping fingolimod) is incorrect because abrupt discontinuation can lead to a rebound in MS activity. Option B (starting high",
    "option_b": "",
    "option_c": "(plasmapheresis) is reserved for cases that are refractory to steroids, and Option D (the marked answer) does not align with current treatment guidelines.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "This case involves a patient with multiple sclerosis (MS) experiencing a relapse in the form of optic neuritis. Optic neuritis is a common inflammatory demyelinating event in MS that typically affects the optic nerve. In MS, demyelinating lesions occur due to autoimmune-mediated inflammation. When the optic nerve is involved, inflammatory demyelination leads to impaired conduction and visual deficits. Although optic neuritis is commonly associated with eye pain, a painless presentation can also occur. The decrease in vision and acuity in one eye, even without pain, is consistent with an MS relapse. In patients on disease-modifying therapies such as fingolimod, it is crucial to manage acute relapses appropriately while maintaining long-term therapy to avoid rebound activity. Diagnosis is primarily clinical, based on visual symptoms, a history of MS, and findings from an ophthalmologic evaluation and possibly visual evoked potentials. Differential diagnoses include ischemic optic neuropathy and compressive optic neuropathies; however, the patient\u2019s history of MS makes optic neuritis most likely. The established first-line treatment for an MS relapse presenting as optic neuritis is high-dose intravenous corticosteroids (e.g., IV methylprednisolone 1 g daily for 3-5 days). Steroids reduce inflammation and hasten recovery. In pregnancy, high-dose steroids can be used with careful monitoring, and it is generally advised not to stop fingolimod abruptly because of the risk of rebound demyelination. Option A (stopping fingolimod) is incorrect because abrupt discontinuation can lead to a rebound in MS activity. Option B (starting high-dose corticosteroids) is the correct approach to managing an acute optic neuritis relapse. Option C (plasmapheresis) is reserved for cases that are refractory to steroids, and Option D (the marked answer) does not align with current treatment guidelines. 1. High-dose IV steroids are the cornerstone of treatment for acute optic neuritis in MS. 2. Not all optic neuritis cases present with pain. 3. Abrupt discontinuation of fingolimod may trigger a severe rebound relapse. Recent clinical guidelines and studies reaffirm the role of high-dose corticosteroids for treating acute optic neuritis in MS. Research also cautions against the premature discontinuation of fingolimod due to the potential for rebound demyelination.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "50's male with progressive LL weakness with sensory level up to T10. No UL involvement. MRI spine thoracic and conus hyperintensity surrounded by hypointense rim. Exam upgoing plantar with absent reflexes LL. What is the diagnosis?",
    "option_a": "Dural AVF",
    "option_b": "PPMS",
    "option_c": "Mercury poisoning",
    "option_d": "Arsenic poisoning",
    "option_e": "Other",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This clinical scenario is suggestive of a spinal dural arteriovenous fistula (DAVF), a type of vascular malformation that typically presents with a progressive myelopathy. DAVF is created by an abnormal shunt between a dural artery and a radicular vein, leading to venous hypertension. This results in spinal cord congestion, edema, and ischemia, which over time cause progressive neurological deficits. The MRI finding of a hyperintense signal surrounded by a hypointense rim is indicative of these chronic vascular changes. The patient\u2019s symptoms\u2014including progressive lower limb (LL) weakness, a sensory level up to T10, and mixed upper motor neuron signs (upgoing plantar responses) along with diminished reflexes\u2014are typical for DAVF. DAVF is most frequently seen in middle-aged or older men. Initial evaluation is done with spinal MRI, which may reveal T2 hyperintensities with a hypointense rim. The differential diagnoses include transverse myelitis, spinal cord neoplasms, and demyelinating diseases such as MS. Definitive diagnosis is made by spinal angiography, which visualizes the abnormal vascular shunt. The treatment of choice is endovascular embolization, with surgical ligation being an alternative if endovascular techniques fail or are not feasible. In pregnant patients, the risks of radiation exposure during endovascular procedures need to be balanced against the risk of neurological deterioration; surgical treatment may be considered under strict monitoring. Option A (Dural AVF) is correct as it best explains the clinical presentation and MRI findings. Option B (Primary Progressive MS) typically does not present with a clear sensory level and the described imaging features. Options C (Mercury poisoning) and D (Arsenic poisoning) are not associated with the focal myelopathic pattern seen here, and Option E (Other) is too vague. 1. Spinal DAVF should be suspected in older males with progressive myelopathy and a defined sensory level. 2. MRI findings of T2 hyperintensity with a hypointense rim are characteristic. 3. Early intervention is crucial to prevent irreversible spinal cord damage. Recent research has demonstrated that early diagnosis and treatment of DAVFs via endovascular or surgical methods significantly improve neurological outcomes. Advances in MRI technology and spinal angiography have enhanced early detection rates.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "SLE patient complicated by nephritis having acute behavioral change and seizures. CSF shows \"lymphocytosis\" (no number) and positive OCB. MRI unilateral temporal hyperintensity and normal MRV. What is the most likely diagnosis?",
    "option_a": "HSV encephalitis",
    "option_b": "SLE cerebritis",
    "option_c": "PRES",
    "option_d": "CVT",
    "option_e": "Other",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question involves an SLE patient with nephritis who presents with acute neuropsychiatric symptoms, including behavioral changes and seizures. The differential diagnosis in such immunocompromised patients includes viral infections like herpes simplex virus (HSV) encephalitis. HSV encephalitis is caused by the herpes simplex virus invading the brain, with a predilection for the temporal lobes. The resulting inflammation, necrosis, and edema typically involve the limbic structures, explaining the unilateral temporal hyperintensity seen on MRI. CSF findings usually include lymphocytic pleocytosis and may show oligoclonal bands. The patient\u2019s clinical picture\u2014acute behavioral change, seizures, and unilateral temporal lobe involvement on MRI\u2014is highly suggestive of HSV encephalitis rather than SLE cerebritis, which would more likely present as a more diffuse or multifocal process. The diagnostic workup includes CSF analysis (with lymphocytic pleocytosis and PCR testing for HSV), MRI with temporal lobe involvement, and exclusion of other causes such as PRES (typically parieto-occipital involvement) or cerebral venous thrombosis (CVT) which shows different vascular imaging findings. SLE cerebritis is another consideration but does not usually yield the unilateral temporal pattern seen here. Immediate initiation of IV acyclovir is the standard of care and has been shown to significantly reduce morbidity and mortality. In SLE patients, careful management of immunosuppression is essential. In pregnancy and lactation, acyclovir is generally considered safe (Pregnancy Category B) and should be used promptly when HSV encephalitis is suspected. Option A (HSV encephalitis) is the correct diagnosis owing to the unilateral temporal lobe hyperintensity on MRI, compatible CSF findings, and clinical presentation. Option B (SLE cerebritis) would usually present with a more diffuse pattern rather than isolated temporal involvement. Options C (PRES) and D (CVT) do not match the imaging or clinical picture, and Option E (Other) is non-specific. 1. Unilateral temporal lobe hyperintensity is highly characteristic of HSV encephalitis. 2. Rapid initiation of IV acyclovir is critical and can be life-saving. 3. Immunocompromised patients, such as those with SLE on immunosuppressants, are at increased risk for opportunistic infections including HSV. Recent guidelines strongly advocate for the early administration of IV acyclovir following clinical suspicion of HSV encephalitis. Advances in CSF PCR technology have improved diagnostic accuracy, allowing for timely intervention that significantly improves patient outcomes.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Similar stem but added that gyne US showed Ovarian tumor What is the treatment?",
    "option_a": "Oopherectomy",
    "option_b": "IVIG",
    "option_c": "PLEX",
    "option_d": "Steroids",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question is based on the understanding of anti\u2010NMDA receptor encephalitis \u2013 an autoimmune encephalitis most often found in young females that is frequently paraneoplastic in nature. The discovery of an ovarian tumor (commonly a teratoma) is a key feature that directs the clinician toward a paraneoplastic etiology. In anti\u2010NMDA receptor encephalitis, the patient\u2019s immune system erroneously produces antibodies against NMDA receptors in the brain. Ovarian teratomas may contain neural tissue that expresses NMDA receptor epitopes; this triggers an autoimmune response that cross-reacts with native receptors, leading to receptor internalization, synaptic dysfunction, and the encephalitic syndrome. Patients typically present with a subacute onset of psychiatric symptoms, seizures, memory deficits, and movement disorders. The detection of an ovarian mass on gynecologic ultrasound in a young female raises the suspicion for a teratoma, reinforcing the diagnosis of anti\u2010NMDA receptor encephalitis. The evaluation involves brain imaging (often showing nonspecific findings), cerebrospinal fluid analysis to detect anti\u2010NMDA receptor antibodies, EEG showing diffuse slowing or epileptiform activity, and ancillary investigations including pelvic imaging. Differential diagnoses include viral encephalitis, primary psychiatric disorders, and other forms of autoimmune encephalitis. The mainstay of treatment is the prompt removal of the tumor \u2013 in this case, an oophorectomy. This is followed by immunomodulatory therapies (first\u2010line: high-dose corticosteroids, IVIG, and plasma exchange) for control of the autoimmune process. For patients who are pregnant or lactating, tumor resection is considered safe in experienced hands and immunotherapy may be adjusted (for example, IVIG is generally safe in pregnancy) with careful multidisciplinary management. Option A (Oophorectomy) is correct because tumor removal eliminates the antigenic source driving the autoimmune response. Options B (IVIG), C (PLEX), and D (Steroids), while important as adjunctive immunotherapies, are not the definitive treatment in the presence of an ovarian teratoma. \u2022 Early identification and resection of the ovarian teratoma lead to improved neurological outcomes. \u2022 Anti\u2010NMDA receptor encephalitis should be suspected in young females with new-onset psychiatric symptoms and seizures. \u2022 Immunotherapy and tumor removal together are key to recovery. Recent research and guidelines emphasize a combined approach that includes early tumor resection along with first-line immunotherapies. Studies have shown that prompt surgical management improves long-term neurological outcomes, and current guidelines support the use of IVIG, steroids, and plasmapheresis as adjunctive treatments.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "26 Young lady with SLE complained of seizures and confusion this time. SLE nephritis on dialysis. What is your diagnosis? This q came 4 times with different images",
    "option_a": "High bp with MRI of PRESs",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question examines the recognition of Posterior Reversible Encephalopathy Syndrome (PRES), a clinico-radiological syndrome that is common in patients with conditions such as SLE, especially when complicated by renal failure and hypertension. PRES is primarily driven by a breakdown of cerebral autoregulation in the setting of severe hypertension, leading to endothelial dysfunction and vasogenic edema. In patients on dialysis or with renal impairment, abrupt fluctuations in blood pressure can precipitate this syndrome. A young female with SLE nephritis on dialysis who presents with seizures and confusion is highly suggestive of PRES. The typical MRI findings include symmetric hyperintensities in the parieto-occipital regions that represent vasogenic edema. Differential diagnoses include lupus cerebritis (neuropsychiatric SLE), metabolic encephalopathy, and infectious causes. PRES is distinguished by its characteristic neuroimaging findings and association with acute hypertension, whereas lupus cerebritis may show other patterns and is more related to intrinsic SLE activity. The primary management of PRES is the rapid and careful reduction of blood pressure using agents such as labetalol or nicardipine (with dose adjustments for patients on dialysis). Supportive care and seizure control are also essential. In pregnant or lactating individuals, antihypertensive choices should consider fetal safety (e.g., labetalol and hydralazine are typically preferred in pregnancy). Option A (High BP with MRI of PRES) is correct because it directly addresses the hypertensive etiology and the imaging findings typical of PRES. Other options (not provided) would be less fitting in this scenario, especially given the clear association with blood pressure changes in a dialysis-dependent SLE patient. \u2022 PRES is reversible with prompt blood pressure control and removal of triggering factors. \u2022 In patients with SLE and renal failure, PRES should be high on the differential when seizures and confusion occur. \u2022 Timely neuroimaging is crucial for the correct diagnosis. Current guidelines stress the importance of rapid hypertension control in the management of PRES. Recent studies have demonstrated improved outcomes with early detection and intervention, and management protocols remain focused on supportive measures and blood pressure stabilization.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Young female with subacute behavioral change admitted under psych MRI mesial temporal hyperintensity The suspected condition is Associated with which tumor?",
    "option_a": "Ovarian teratoma",
    "option_b": "Lung CA",
    "option_c": "Breast Ca",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question focuses on limbic encephalitis, particularly the type that is paraneoplastic. In a young female with subacute behavioral changes and mesial temporal hyperintensity on MRI, anti\u2010NMDA receptor encephalitis is a leading consideration, classically associated with ovarian teratomas. In paraneoplastic limbic encephalitis, antibodies generated against antigens expressed by a tumor (such as an ovarian teratoma) cross-react with neuronal cell surface or synaptic proteins in the limbic system. This immune-mediated attack causes inflammation and dysfunction in the temporal lobes, explaining the neuropsychiatric symptoms. Patients often present with a mix of psychiatric symptoms (such as anxiety, psychosis, or behavioral changes), memory deficits, and seizures. The MRI finding of mesial temporal hyperintensity supports involvement of limbic structures, and the presence of an ovarian tumor clinches the paraneoplastic association. The differential includes viral encephalitis (e.g., herpes simplex encephalitis), primary psychiatric conditions, and other autoimmune encephalitides. Key investigations include CSF studies for autoantibodies, EEG, and detailed neuroimaging. Pelvic imaging is used to search for the associated teratoma. Management involves removal of the underlying tumor (oophorectomy) combined with immunotherapy (first-line agents include high-dose corticosteroids, IVIG, or plasmapheresis). In pregnant or lactating patients, surgical management is approached with multidisciplinary coordination; immunotherapy regimens may be adjusted to minimize fetal exposure while still controlling the disease. Option A (Ovarian teratoma) is correct because it is classically associated with anti\u2010NMDA receptor encephalitis presenting with limbic encephalitis. Options B (Lung CA) and C (Breast Ca) are more typically linked to other paraneoplastic syndromes and are not characteristic in this young female demographic. \u2022 Always consider autoimmune encephalitis in young females with acute psychiatric symptoms and temporal lobe changes on MRI. \u2022 Early detection and removal of an ovarian teratoma can dramatically improve outcomes. \u2022 Limbic encephalitis has a distinct antibody profile that aids in its diagnosis. Recent studies reinforce the benefit of combining tumor removal with immunotherapy in anti\u2010NMDA receptor encephalitis. There is ongoing research into the long-term outcomes of early intervention, and current guidelines continue to support a multidisciplinary approach for optimal patient recovery.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Young lady with SLE complained of seizures and confusion this time. SLE nephritis on dialysis. What is your diagnosis? This q came 4 times with different images.",
    "option_a": "lupus cerebritis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "This question again addresses an encephalopathic presentation in a young patient with SLE on dialysis. The clinical scenario \u2013 seizures and confusion in the setting of SLE nephritis \u2013 can be due to either neuropsychiatric lupus (lupus cerebritis) or a secondary process such as Posterior Reversible Encephalopathy Syndrome (PRES). In PRES, the key mechanism is a failure of cerebral autoregulation due to severe hypertension (often seen in patients with renal failure or those undergoing dialysis) leading to vasogenic edema, most commonly in the posterior cerebral regions. Lupus cerebritis, on the other hand, is driven by direct autoimmune inflammation of the central nervous system. In a dialysis patient with likely labile blood pressures, PRES becomes the more likely diagnosis. The presentation of seizures and confusion in an SLE patient with nephritis on dialysis typically suggests a hypertensive encephalopathy pattern rather than isolated lupus cerebritis. MRI findings in PRES characteristically demonstrate symmetric hyperintensities in the parieto-occipital lobes, a pattern that is less typical of lupus cerebritis. The differential diagnosis primarily includes PRES versus neuropsychiatric SLE (lupus cerebritis). A detailed history focusing on blood pressure fluctuations, renal function, and dialysis schedules, along with neuroimaging (MRI), is essential to differentiate these conditions. Laboratory studies and CSF analysis can be supportive in diagnosing lupus cerebritis, but the radiologic pattern is key in identifying PRES. Management of PRES focuses on rapid yet controlled blood pressure reduction and supportive care, including seizure management. First-line antihypertensive agents (such as labetalol or nicardipine) are indicated, with careful adjustment in patients on dialysis. In pregnant or lactating patients, antihypertensives with proven fetal safety (e.g., labetalol, hydralazine) should be used, and seizure control should be maintained with medications that have a known safety profile in pregnancy. Option A (lupus cerebritis) is less favored given the strong clinical association of dialysis-related hypertension with PRES. Although neuropsychiatric SLE does occur, the presence of severe hypertension and the typical MRI findings lean the diagnosis toward PRES. The marked answer was B, which likely stands for the option that corresponds to 'High BP with MRI findings of PRES', making it the correct choice. \u2022 PRES is a reversible condition if diagnosed early and managed promptly with blood pressure control. \u2022 In SLE patients with renal failure, fluctuating blood pressure is a common trigger for PRES. \u2022 Distinguishing PRES from lupus cerebritis is crucial as the management strategies differ significantly. Latest research reinforces that in patients with SLE on dialysis, the presentation of seizures and confusion is most often related to hypertensive encephalopathy (PRES). Updated guidelines recommend rapid blood pressure stabilization and supportive care, which have been associated with favorable outcomes when intervention occurs early.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "female with pic of miller fisher asked about treatment",
    "option_a": "IVIG",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barr\u00e9 syndrome (GBS) characterized by the classic clinical triad of ophthalmoplegia, ataxia, and areflexia. It is believed to be an immune-mediated neuropathy where antibodies attack peripheral nerves, particularly those involved in eye movement and coordination. The underlying mechanism of MFS involves molecular mimicry, whereby an antecedent infection (often Campylobacter jejuni or other viral triggers) leads to the formation of anti-ganglioside antibodies, especially anti-GQ1b. These antibodies target nerve components, disrupting nerve conduction predominantly in cranial nerves and leading to the characteristic clinical features. Patients often present with diplopia due to ophthalmoplegia, unsteady gait from ataxia, and diminished or absent deep tendon reflexes. Although the condition usually follows a benign and self-limiting course, early recognition is important as some cases may progress or require supportive care, particularly if there is any respiratory involvement. Diagnosis is largely clinical, supported by the detection of anti-GQ1b antibodies in the serum. Electrophysiological studies may help confirm a demyelinating process if ambiguity exists. The differential diagnoses include conditions such as myasthenia gravis (characterized by fatigable weakness and improvement with rest), brainstem stroke, and botulism. Each can be differentiated by specific clinical features and confirmatory tests (e.g., anti-AChR antibodies for myasthenia gravis, neuroimaging for stroke, and toxin assays for botulism). The mainstay of treatment for MFS\u2014particularly when symptoms are severe or progressive\u2014is supportive care and immunotherapy. First-line treatment options include intravenous immunoglobulin (IVIG) and plasmapheresis. IVIG is preferred in many cases because of its ease of administration and favorable safety profile, including in special populations such as pregnant and lactating women. In mild cases, the syndrome may be self-limiting, but early immunotherapy (IVIG) is used to accelerate recovery and prevent complications. Second-line options, such as plasmapheresis, may be considered if IVIG is contraindicated or ineffective. Pregnancy and lactation considerations: IVIG is considered safe during pregnancy and breastfeeding, making it a suitable choice for these populations. Option A (IVIG) is correct because IVIG is widely accepted as a first-line treatment for Miller Fisher syndrome, particularly when intervention is warranted. The absence of other options makes it clear that the intended answer is IVIG. Plasmapheresis is an alternative but is less commonly used first-line due to logistical challenges and less favorable tolerability in some patients, including pregnant individuals. 1. Over 80% of patients with Miller Fisher syndrome have anti-GQ1b antibodies, which can help confirm the diagnosis. 2. Despite its alarming initial presentation, MFS typically has a favorable prognosis with appropriate supportive care, and full recovery is common. 3. IVIG is not only effective but also safe during pregnancy and lactation, making it the treatment of choice in these populations. Recent research and updated guidelines reinforce the role of IVIG in managing Guillain-Barr\u00e9 syndrome variants, including Miller Fisher syndrome. Studies suggest that early treatment with IVIG may hasten recovery and reduce the risk of complications. Although some patients with mild MFS may recover without immunotherapy, the consensus remains that IVIG is indicated when significant neurological deficits are present or when rapid progression is observed.",
    "exam_year": "2023",
    "exam_type": "Promotion"
  },
  {
    "question": "Young boy, with 4th nerve palsy, where is the tumor?",
    "option_a": "Midbrain",
    "option_b": "Pons",
    "option_c": "Medulla",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "The fourth cranial (trochlear) nerve is unique as it is the only cranial nerve that emerges dorsally from the brainstem, specifically from the midbrain. Its primary function is to innervate the superior oblique muscle, which is involved in downward and inward eye movement. In a young patient presenting with an isolated fourth nerve palsy, a lesion in the midbrain area is highly suspect. Tumors in the midbrain, such as pineal region tumors or tectal gliomas, can compress the trochlear nerve along its course. Due to its dorsal exit, even small lesions in the midbrain can affect the nerve. This compression disrupts the normal innervation of the superior oblique, leading to misalignment of the eyes and dysfunctional ocular motility. Studies have shown that midbrain lesions are often responsible for atypical presentations of cranial nerve palsies in pediatric populations. Clinically, patients may present with vertical diplopia (double vision, particularly when looking down or crossing the eyes) and may adopt an abnormal head posture to compensate. In children, these signs are often accompanied by other features of dorsal midbrain syndrome, such as light-near dissociation, which collectively support a midbrain localization. The diagnosis relies on a careful neurologic examination and is confirmed using high-resolution MRI of the brain. Differential diagnoses include other brainstem lesions like demyelinating diseases or vascular malformations, but the clinical setting of a young boy with isolated fourth nerve involvement points strongly towards a compressive midbrain lesion. Management starts with accurate neuroimaging (MRI) to localize and characterize the tumor. First-line treatment is usually neurosurgical evaluation for biopsy and possible resection, with adjuvant therapies (radiation/chemotherapy) considered based on final pathology. Although pregnancy and lactation considerations are not applicable in a young boy, in female patients of childbearing age with similar brainstem tumors, treatment planning would include multidisciplinary discussions regarding the timing of surgery and the safety of radiation therapies during pregnancy and lactation. Option A (Midbrain) is correct because the trochlear nerve originates from the dorsal midbrain. Option B (Pons) is incorrect as the 4th nerve does not arise from the pons; Option C (Medulla) is also incorrect based on anatomical location. 1. The trochlear nerve is the smallest and the only cranial nerve with a dorsal exit from the brainstem. 2. Pineal region tumors may present with signs of dorsal midbrain syndrome, including vertical gaze abnormalities. Recent neuroimaging advances and molecular profiling have enhanced the identification and characterization of pediatric brain tumors. Updated guidelines emphasize early MRI for suspicious cranial nerve deficits, and contemporary studies advocate for multidisciplinary treatment approaches to optimize outcomes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Picture of this MRI:\n\nWhat is your diagnosis?",
    "option_a": "Cavernous angioma",
    "option_b": "Venous malformation",
    "option_c": "AVM",
    "option_d": "Cavernous malformation",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Cerebral cavernous malformations, also known as cavernous angiomas, are clusters of abnormal, dilated blood vessels that form a benign vascular malformation in the brain. Despite the presence of two terms in the options (cavernous angioma and cavernous malformation), they refer to the same entity. These lesions are characterized by thin-walled, sinusoidal vascular channels without intervening neural tissue. They frequently undergo small, repeated hemorrhages leading to a classic \u2018popcorn\u2019 appearance on MRI with mixed signal intensities and a hemosiderin rim. This bleeding tendency is due to the lack of normal vascular wall structure and supporting tissue. Patients with cavernous malformations may present with seizures, focal neurological deficits, or hemorrhagic symptoms. The typical imaging features on MRI serve as a reliable correlate with these clinical manifestations. The presence of a lesion with a popcorn-like appearance on MRI points strongly towards a cavernous malformation. MRI is the gold standard for diagnosing vascular malformations. Differential diagnoses include developmental venous anomalies (often seen as a caput medusae configuration) and arteriovenous malformations (AVMs), which typically demonstrate high flow and robust enhancement. The absence of high flow dynamics helps differentiate cavernous malformations from AVMs. Management is based on the lesion's size, location, and symptomatology. Asymptomatic lesions are usually managed conservatively with periodic imaging. Symptomatic lesions (with seizures or neurological deficits) may require surgical resection. In pregnant patients, conservative management is preferred unless there is significant hemorrhage or neurological compromise, as surgical intervention carries additional risks. Option A (Cavernous angioma) is correct and synonymous with option D (Cavernous malformation). Option B (Venous malformation) refers to developmental venous anomalies and has a different imaging appearance. Option C (AVM) is incorrect because arteriovenous malformations are high-flow lesions and have a distinct radiologic profile. 1. Cavernous malformations demonstrate a classic \u2018popcorn\u2019 appearance with mixed signal intensities on MRI. 2. They are prone to small hemorrhages, which contribute to their characteristic imaging features. Recent research focuses on the genetic underpinnings and natural history of cavernous malformations. Updated guidelines advocate for the use of advanced MRI techniques in diagnosis and emphasize an individualized approach to management, particularly in cases complicated by pregnancy or recurrent hemorrhage.",
    "exam_year": "2018",
    "exam_type": "Part I",
    "image_url": "page_6.png"
  },
  {
    "question": "Tumor pathology showing pseudorosette what is the diagnosis:",
    "option_a": "Ependymoma",
    "option_b": "Meningioma",
    "option_c": "Astrocytoma",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Pseudorosettes are a histological pattern where tumor cells are arranged around blood vessels, separated by thin zones of cytoplasmic processes. This pattern is a classic feature of ependymomas, distinguishing them from other central nervous system tumors. Ependymomas arise from the ependymal cells lining the ventricular system and central canal of the spinal cord. The formation of perivascular pseudorosettes is due to the tumor cells\u2019 tendency to align around small blood vessels, reflecting the tumor\u2019s growth pattern and the microenvironment influenced by vascular structures. This characteristic is helpful in differentiating ependymomas from other glial tumors. Patients with ependymomas can present with symptoms related to obstruction of cerebrospinal fluid pathways (leading to hydrocephalus) or focal neurological deficits from compression of adjacent neural structures. In the spinal cord, these tumors can lead to segmental weakness and sensory changes. Diagnosis is made by tissue biopsy and subsequent histopathology. Immunohistochemical staining for GFAP and other markers supports the diagnosis. Differential diagnoses include astrocytomas (which show diffuse growth and lack specific rosette patterns) and meningiomas (which typically show whorled patterns and psammoma bodies). The mainstay of treatment is maximal safe surgical resection. Postoperative radiotherapy is often recommended, especially in cases of incomplete resection. In pediatric cases, consideration is given to the long-term effects of radiation; hence, management is multidisciplinary. For pregnant or lactating patients who present later in life with these tumors, treatment may be deferred or modified to minimize fetal exposure to radiation and surgical risks. Option A (Ependymoma) is correct because pseudorosettes are a hallmark feature of these tumors. Option B (Meningioma) is incorrect as meningiomas typically show whorled or psammomatous patterns, not pseudorosettes. Option C (Astrocytoma) is incorrect because astrocytomas lack the specific pseudorosette formation seen in ependymomas. 1. The presence of perivascular pseudorosettes is highly suggestive of ependymoma. 2. Differentiation from astrocytoma is critical, as treatment strategies and prognoses differ significantly. Recent advancements in molecular diagnostics have begun to stratify ependymomas into subgroups with distinct prognostic and therapeutic implications. Current guidelines recommend surgical resection as the first step, with adjuvant radiation reserved for high-grade lesions or residual tumor.",
    "exam_year": "2018",
    "exam_type": "Part I"
  }
]